PHIO
NASDAQPhio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (PHIO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 11 wire items for PHIO, including 5 press releases and news items, 3 SEC filings and 2 insider trades. The most recent was published Nov 10, 2026.
Price$0.84-0.00 (-0.25%)
02:45 PM04:30 PM
Financial highlights
Full financials- Net income, TTM
- -$14.67M
- Free cash flow, TTM
- -$12.40M
- Cash
- $10.61M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks49-47%
2026-05-172026-11-08
Mix3190d
- Insider13(42%)
- Other11(35%)
- SEC Filings6(19%)
- Earnings1(3%)
Activity · 52 weeks9762 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERDirector Plott Ronald Todd bought $15,189 worth of shares (18,300 units at $0.83), increasing direct ownership by 44% to 60,300 units (SEC Form 4)4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- INSIDERChairman, Pres. & CEO Bitterman Robert J bought $20,500 worth of shares (25,000 units at $0.82), increasing direct ownership by 3% to 789,871 units (SEC Form 4)4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- PRPhio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual MeetingINTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical FatigueKing of Prussia, Pennsylvania--(Newsfile Corp. - November 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that clinical data from its Phase 1b trial were presented at the 2026 Annual Meeting of the American Society for Dermatologic Surgery (ASDS), held in San Diego, California, from November 5-8, 2026."The growing body of clinical evidence supporting PH-762 continues to demon
- PRPhio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Phoenix, Arizona from November 6-8, 2026."The growing body of clinical evidence suggests that PH-762 may offer patients and physicians a meaningful new treatmen
- SECSEC Form 10-Q filed by Phio Pharmaceuticals Corp.10-Q - Phio Pharmaceuticals Corp. (0001533040) (Filer)
- SECPhio Pharmaceuticals Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
- PRPhio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study InitiationPH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents to FDAKing of Prussia, Pennsylvania--(Newsfile Corp. - November 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biopharmaceutical company developing therapeutic products based on its proprietary INTASYL® gene-silencing technology to eliminate cancer, today reported financial results for the quarter ended September 30, 2026, and provided a business update."We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study i
- PRPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesLive Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA therapeutic platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session."We look forward to engaging with investors at the Renmark F
- SECSEC Form 8-K filed by Phio Pharmaceuticals Corp.8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
- PRPhio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug SubstanceCritical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next stage of clinical development.The batch was manufactured in accordance with
- PROTC Markets Group Announces Third Annual Global Markets Forum Presentations Now Available On DemandNEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the third annual Global Markets Forum, held October 7–8, 2026, are now available for on-demand viewing. The event was presented in partnership with Aquis Stock Exchange, BME, Canadian Securities Exchange (CSE), OTC Markets Group, and SIX Swiss Exchange. The two-day event brought together C-suite executives from leading European and Canadian public growth companies to share insights into their businesses, growth strategies, and market opportunities with a global investor audience. The October 7 hybrid program featured company
- PRPhio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio's INTASYL® siRNA therapeutic platform, its differentiated delivery approach, and the Company's strategic direction at The Global Markets Virtual Forum hosted by www.VirtualInvestorConferences.com (VIC) on October 8th, 20
- PROTC Markets Group Announces Agenda for Third Annual Global Markets Forum, October 7th & 8thNEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the third annual Global Markets Forum, taking place October 7–8, 2026, in partnership with Aquis Stock Exchange, BME, Canadian Securities Exchange (CSE), OTC Markets Group, and SIX Swiss Exchange. The two-day event will bring together C-suite executives from leading European and Canadian public growth companies to share insights into their businesses, growth strategies, and market opportunities with a global investor audience. On Wednesday, October 7, the forum will be hosted in person at the OTC Markets Group Office in New York City
- PRPhio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd ConferenceHighlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that it has accepted the invitation to present at the National Investment Banking Association's (NIBA) 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida.Robert Bitterman, President and Chief Executive Officer, will present Phio's INTASYL® siRNA therapeutic platform, its diff
- INSIDERDirector Plott Ronald Todd bought $10,350 worth of shares (10,000 units at $1.03), increasing direct ownership by 31% to 42,000 units (SEC Form 4)4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- INSIDERChairman, Pres. & CEO Bitterman Robert J was granted 400,000 shares, increasing direct ownership by 110% to 764,871 units (SEC Form 4)4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- INSIDERChief Financial Officer Carson Lisa Cabott was granted 108,000 shares, increasing direct ownership by 133% to 189,112 units (SEC Form 4)4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- INSIDERDirector Plott Ronald Todd was granted 17,000 shares, increasing direct ownership by 113% to 32,000 units (SEC Form 4)4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- SECSEC Form S-8 filed by Phio Pharmaceuticals Corp.S-8 - Phio Pharmaceuticals Corp. (0001533040) (Filer)
- SECPhio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
- INSIDERSEC Form 4 filed by Phio Pharmaceuticals Corp.4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- INSIDERChairman, Pres. & CEO Bitterman Robert J bought $2,058 worth of shares (2,000 units at $1.03), increasing direct ownership by 0.55% to 364,871 units (SEC Form 4)4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- PRPhio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 ConferenceCompany to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania.Robert Bitterman, President and Chief Executive Officer, will provide an update on the Company's completed Phase 1b clinical study of PH-762
- INSIDERDirector Bradford Patricia A bought $12,360 worth of shares (12,000 units at $1.03), increasing direct ownership by 26% to 57,651 units (SEC Form 4)4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
- INSIDERChairman, Pres. & CEO Bitterman Robert J covered exercise/tax liability with 68,550 shares, decreasing direct ownership by 16% to 362,871 units (SEC Form 4) to satisfy withholding tax4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
PHIO FAQ
9 questionsWhat does Phio Pharmaceuticals Corp. do?
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762, which targets the checkpoint protein PD-1 that prevent T cells from attacking various cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that prevent cancer cells...What is the latest news on PHIO?
In the last 30 days Quantisnow tracked 11 wire items for PHIO: 5 press releases and news items, 3 SEC filings, 2 insider trades and 1 earnings update. The most recent was published on November 10, 2026.Is PHIO profitable?
No. Phio Pharmaceuticals Corp. reported a net loss of $14.67M for the twelve months ended Sep 30, 2026.How much cash and debt does PHIO have?
Phio Pharmaceuticals Corp. reported $10.61M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PHIO stock trade?
Phio Pharmaceuticals Corp. (PHIO) is listed on NASDAQ.What sector and industry is PHIO in?
Phio Pharmaceuticals Corp. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PHIO?
Phio Pharmaceuticals Corp. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $14.00 price target on 2025-06-05. Recent price targets cluster around $14.00.What companies are similar to PHIO?
Notable peers in the same industry include ATRA (Atara Biotherapeutics Inc.), CGEN (Compugen Ltd.), IOVA (Iovance Biotherapeutics Inc.). Compare PHIO side-by-side with any of them on Quantisnow.How can I track PHIO on Quantisnow?
Quantisnow aggregates Phio Pharmaceuticals Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PHIO to receive live email and push alerts on every new disclosure.